Want to see ALGS full AI Analyst Report?
ALGS Stock Chart & Stats
$4.08
-$0.61(-13.01%)
At close: 4:00 PM EDT
$4.08
-$0.61(-13.01%)
Day’s Range― - ―
52-Week Range$3.98 - $13.69
Previous CloseN/A
Volume203.10K
Average Volume (3M)223.79K
Market Cap
$26.30M
Enterprise Value$26.56
Total Cash (Recent Filing)$55.08M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 06, 2026EPS Estimate
-1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.69
Shares Outstanding5,388,223
10 Day Avg. Volume101,329
30 Day Avg. Volume223,790
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.50Price Target Upside1676.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.05
Revenue Forecast (FY)$29.79M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress And Licensing DealFDA Fast Track plus supportive interim Phase 2 data and a regional licensing transaction create durable program de-risking: Fast Track can accelerate review timelines, Phase 2 backing improves clinical confidence, and the $25M upfront plus milestones provides non-dilutive cash and structured future revenue potential.
Modest Leverage / Low Debt BurdenRelatively low debt reduces refinancing and interest obligations, preserving financial flexibility over the medium term. For a clinical-stage biotech that will require funding, modest leverage lowers near-term default risk and gives management optionality to pursue partnerships, licensing, or controlled equity raises without heavy debt stress.
Strong Gross Profitability ProfileVery high gross margins indicate the company’s underlying R&D and potential product economics are favorable: if/when a candidate commercializes, incremental revenues would likely convert strongly to gross profit. That structural margin advantage supports future scalability once fixed R&D and SG&A leverage improves.
Bears Say
Consistent, Heavy Cash BurnSustained negative operating and free cash flow indicates the business continually consumes capital to fund development. Over a 2–6 month horizon this means ongoing dilution or reliance on non-operating cash (partners, equity raises) is likely; persistent burn also constrains ability to invest opportunistically or pivot without external funding.
Ongoing Large Operating And Net LossesMaterial operating and net losses are structural until commercial revenues emerge. This pressure erodes equity and returns on capital, limits reinvestment capacity, and creates long-term financing risk: sustained losses mean management must secure funding repeatedly, which can dilute shareholders and constrain strategic choices.
No Recurring Product Revenue; Reliance On FinancingLack of commercial revenues means the firm’s business model depends on financing, partnerships, or milestones for cash. That structural revenue absence creates high funding sensitivity and revenue volatility, making long-term planning and sustained investment in late-stage development contingent on successful deal-making or capital markets access.
Aligos Therapeutics News
ALGS FAQ
What was Aligos Therapeutics, Inc.’s price range in the past 12 months?
Aligos Therapeutics, Inc. lowest stock price was $3.98 and its highest was $13.69 in the past 12 months.
What is Aligos Therapeutics, Inc.’s market cap?
Aligos Therapeutics, Inc.’s market cap is $26.30M.
When is Aligos Therapeutics, Inc.’s upcoming earnings report date?
Aligos Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were Aligos Therapeutics, Inc.’s earnings last quarter?
Aligos Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$2.21 earnings per share for the quarter, beating the consensus estimate of -$2.213 by $0.003.
Is Aligos Therapeutics, Inc. overvalued?
According to Wall Street analysts Aligos Therapeutics, Inc.’s price is currently Undervalued.
Does Aligos Therapeutics, Inc. pay dividends?
Aligos Therapeutics, Inc. does not currently pay dividends.
What is Aligos Therapeutics, Inc.’s EPS estimate?
Aligos Therapeutics, Inc.’s EPS estimate is -1.09.
How many shares outstanding does Aligos Therapeutics, Inc. have?
Aligos Therapeutics, Inc. has 5,388,223 shares outstanding.
What happened to Aligos Therapeutics, Inc.’s price movement after its last earnings report?
Aligos Therapeutics, Inc. reported an EPS of -$2.21 in its last earnings report, beating expectations of -$2.213. Following the earnings report the stock price went up 6.799%.
Which hedge fund is a major shareholder of Aligos Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
ALGS Stock 12 Month Forecast
Average Price Target
$72.50
▲(1676.96% Upside)
Technical Analysis
Medicinova
―
Celularity
―
Barinthus Biotherapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
46.67%
Insiders
4.22% Mutual Funds
31.17% Other Institutional Investors
14.58% Public Companies and
Individual Investors